Shots:
- Seed Therapeutics to receive $10M upfront, $10M equity investment, ~$780M as pre/clinical development, regulatory & commercial milestones along with royalties on net sales of products that emerges from the collaboration
- Seed utilizes molecular glue protein degradation technology to develop potential new therapies
- The agreement allows Seed to advance its platform to deliver new molecules targeting proteins that cause human diseases
Click here to read full press release/ article | Ref: Globe Newswire | Image: Medium
The post Eli Lilly Signs a License Agreement with Seed Therapeutics for Protein Degradation-Based Therapies first appeared on PharmaShots.
